Livzon Pharmaceutical Group
9
24M
6
0.23
4
0.33
- Areas of investment
Summary
Livzon Pharmaceutical Group appeared to be the Corporate Investor, which was created in 1985. The main office of represented Corporate Investor is situated in the Zhuhai. The fund was located in Asia if to be more exact in China.
Among the most popular fund investment industries, there are Medical, Health Diagnostics. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Elicio Therapeutics, Cynvenio Biosystems. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 2-3 partakers. The meaningful sponsors for the fund in investment in the same round are Syno Capital, Greenwoods Asset Management, EFung Capital.
The important activity for fund was in 2015. Considering the real fund results, this Corporate Investor is 47 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year.
Investments analytics
Analytics
- Total investments
- 9
- Lead investments
- 4
- Rounds per year
- 0.23
- Follow on index
- 0.33
- Investments by industry
- Health Care (7)
- Biotechnology (6)
- Medical (5)
- Therapeutics (4)
- Life Science (3) Show 8 more
- Investments by region
-
- United States (5)
- China (4)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Group Appearance index
- 0.89
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| St Phi Therapeutics | 01 Jun 2019 | Seed | Shanghai, Shanghai, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.